Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04638998 · ClinicalTrials.gov registry record
Assessing Neuroinflammation in GWI Using MRS
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 49
- Enrollment target
NCT04638998: Completed study, sponsored by University of Alabama at Birmingham.
NCT04638998 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04638998 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 49 participants
- Enrollment target
Study Summary
The primary aim of this study is to determine if Gulf War Illness (GWI) likely involves neuroinflammation. The investigators hypothesize that GWI involves neuroinflammation. By assessing the five neuroinflammatory outcomes across the brain, the investigators can determine if there are focal or global signs of one or more neuroinflammatory markers in the brains of individuals with GWI. This neuroimaging technique may allow investigators and others to detect cases of GWI neuroinflammation, which would improve treatment decisions as well as the development of new targeted therapies. It is an ideal diagnostic tool because it has low patient risk, is noninvasive, can be used repeatedly in longitudinal studies, provides whole-brain coverage, yields multiple independent markers of inflammation, and can be employed at most hospitals and research neuroimaging suites.
Primary Outcome
The concentration of myoinositol will be measured in the brain using MRI as a measure of neuroinflammation. This will be measured in both the control and experimental groups.
Interventions
- PROCEDURE Blood draw
- PROCEDURE Magnetic Resonance Spectroscopic Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2023-12-31 |
What the finished NCT04638998 record still lists
NCT04638998 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 49 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Blood draw is the first listed.
NCT04638998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04638998 about?
NCT04638998 is a clinical study titled "Assessing Neuroinflammation in GWI Using MRS". The primary aim of this study is to determine if Gulf War Illness (GWI) likely involves neuroinflammation. The investigators hypothesize that GWI involves neuroinflammation. By assessing the five neuroinflammatory outcomes across the brain, the investigators can determine if there are focal or globa...
What is the current status of trial NCT04638998?
This trial is currently completed. The enrollment target is 49 participants. The study started on 2020-12-01. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT04638998?
The interventions under investigation include: Blood draw (PROCEDURE), Magnetic Resonance Spectroscopic Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT04638998?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI